Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States

Clinical Cancer Research

Volumn 15, Issue 14, 2009, Pages 4706-4711

  Mosquera, Juan Miguel ^a,b   Mehra, Rohit ^c   Regan, Meredith M ^b,h   Perner, Sven ^a,b,f   Genega, Elizabeth M ^b,e   Bueti, Gerri ^e   Shah, Rajal B ^c,d   Gaston, Sandra ^b,e   Tomlins, Scott A ^c   Wei, John T ^c,d   Kearney, Michael C ^b,e   Johnson, Laura A ^a   Tang, Jeffrey M ^a   Chinnaiyan, Arul M ^c,d   Rubin, Mark A ^a,b,g,h   Sanda, Martin G ^b,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f UNIVERSITY OF ULM   (Germany)

^g BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUCIN; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ERG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE REARRANGEMENT; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NORTH AMERICA; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TMPRSS2 TUMOR GENE; TUMOR BIOPSY; TUMOR GENE; UNITED STATES;

AGED; BIOPSY; GENE FREQUENCY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ONCOGENE PROTEINS, FUSION; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; TRANS-ACTIVATORS; UNITED STATES;

EID: 68049101459     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2927     Document Type: Article

References (20)

1. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648 (Pubitemid 41528150)
2. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26:4596-4599 (Pubitemid 47037039)
3. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006;66:8337-8341 (Pubitemid 44449140)
4. Cerveira N, Ribeiro FR, Peixoto A, et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006;8:826-832 (Pubitemid 44564838)
5. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007;20:538-544 (Pubitemid 46631996)
6. Rajput AB, Miller MA, De Luca A, et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007;60:1238-1243 (Pubitemid 350084545)
7. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008;27:253-263
8. Nam RK, Sugar L, Yang W, et al. Expression of the TMPRSS2: ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007;97:1690-1695 (Pubitemid 350249347)
9. Mosquera JM, Perner S, Demichelis F, et al. Morphological features of TMPRSS2-ERG gene fusion prostate cancer. J Pathol 2007;212:91-101. (Pubitemid 46746294)
10. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007;31:882-888 (Pubitemid 47165141)
11. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006;66:8347-8351 (Pubitemid 44449142)
12. Svensson M, Perner S, Demichelis F, et al. Frequency of ERG rearrangement in a Swedish hospital based biopsy cohort [abstract 885]. Boston (MA):USCAP; 2009.
13. Fine S, Gopalan A, Leversha M, et al. Are there morphologic correlates of prostate cancer associated with TMPRSS2-ERG molecular abnormalities? [abstract 659]. San Diego (CA): USCAP; 2007.
14. Nigwekar P, Miick S, Rittenhouse H, et al. Morphologic correlates of individual splice variants of TMPRSS2-ERG prostate cancer (PCa) detected by transcription-mediated amplification (TMA) in radical prostatectomy (RP) specimens [abstract 797]. Denver (CO): USCAP; 2008.
15. Barry M, Perner S, Demichelis F, Rubin MA. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 2007;70:630-633 (Pubitemid 350030260)
16. Mosquera JM, Perner S, Genega EM, et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 2008;14:3380-3385
17. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007;13:5103-5108 (Pubitemid 47502077)
18. Laxman B, Morris DS, Yu J, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008;68:645-649 (Pubitemid 351206738)
19. Laxman B, Tomlins SA, Mehra R, et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006;8:885-888
20. Zhou M, Simmerman K, Tsuzuki T, et al. TMPRSS2-ERG gene fusion in prostate cancer of different ethnic groups [abstract 925]. Boston (MA): USCAP; 2009.